Prognostic Models for Renal Cell Carcinoma in the Era of Immune Checkpoint Therapy.

Autor:	Parosanu A; Oncology, Elias Emergency University Hospital, Bucharest, ROU., Stanciu IM; Medical Oncology, Elias Emergency University Hospital, Bucharest, ROU., Pirlog C; Oncology, Elias Emergency University Hospital, Bucharest, ROU., Orlov Slavu C; Oncology, Elias Emergency University Hospital, Bucharest, ROU., Cotan H; Oncology, Elias Emergency University Hospital, Bucharest, ROU., Iaciu C; Oncology, Elias Emergency University Hospital, Bucharest, ROU., Popa AM; Oncology, Elias Emergency University Hospital, Bucharest, ROU., Olaru M; Oncology, Elias Emergency University Hospital, Bucharest, ROU., Moldoveanu O; Urology, Fundeni Clinical Institute, Bucharest, ROU., Catalin B; Urology, Fundeni Clinical Institute, Bucharest, ROU., Nitipir C; Oncology, Elias Emergency University Hospital, Bucharest, ROU.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2022 Oct 29; Vol. 14 (10), pp. e30821. Date of Electronic Publication: 2022 Oct 29 (Print Publication: 2022).
DOI:	10.7759/cureus.30821
Abstrakt:	With recent advances in oncology, immune checkpoint inhibitors (ICIs) have become a milestone in immuno-oncology. Unfortunately, although ICIs have demonstrated improved clinical efficacy in a broad spectrum of cancers, many patients do not respond to this newer therapy. As a result, it is crucial to identify predictive factors of response to immunotherapy in patients with kidney cancer. This review discusses the research investigating potential biomarkers of response to ICIs in renal cell carcinoma. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2022, Parosanu et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu